Riaz Gillani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Riaz Gillani has a total of 216 co-authors. Here are the top co-authors by number of shared publications:
Katherine A. Janeway
Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Boston, MA, USA
48 shared publicationsAlexander Gusev
Cancer Program, Broad Institute of Harvard and MIT
47 shared publicationsJett Crowdis
Harvard Medical School
46 shared publicationsAlma Imamovic
45 shared publications- Bo Kyung Alex Seong
Department of Medical Biophysics, University of Toronto, Toronto, Canada
45 shared publications Brian J. Haas
45 shared publications
Latest Publications
- Open Access
Clustered structural variant hotspots enable oncogenic addiction and plasticity in osteosarcoma
The genomic landscape of osteosarcoma, the most common bone cancer worldwide, is among the most structurally complex of all human malignancies. The identification of recurrent and functionally consequential patterns has thus remained a challenge. Across 236 whole-genome sequencing osteosarcoma samples, we uncovered five genomic hotspots of clustered structural variation collectively altered in 58% of tumors. Four were associated with amplification of oncogenes ( MYC , CCND3 , CCNE1 , CDK4) , while the fifth mapped largely upstream of TP53 . Hotspot events showed coordinated patterns of co-occurrence and mutual exclusivity with each other and with tumor suppressor alterations, suggesting genomic context-specific selection. We found localized transcriptional dysregulation at hotspot event loci, and single cells harboring these events converged on a neural crest-like program, linking these structural alterations to a less differentiated cell state. These events were also detectable non-invasively through liquid biopsies and displayed ongoing structural evolution throughout disease progression, a finding with potential clinical utility. Our results provide novel insight into how complex rearrangements shape oncogenesis in osteosarcoma, with broader relevance to other cancers characterized by complex genomes.
Open AccessClustered structural variant hotspots enable oncogenic addiction and plasticity in osteosarcoma
The genomic landscape of osteosarcoma, the most common bone cancer worldwide, is among the most structurally complex of all human malignancies. The identification of recurrent and functionally consequential patterns has thus remained a challenge. Across 236 whole-genome sequencing osteosarcoma samples, we uncovered five genomic hotspots of clustered structural variation collectively altered in 58% of tumors. Four were associated with amplification of oncogenes ( MYC , CCND3 , CCNE1 , CDK4) , while the fifth mapped largely upstream of TP53 . Hotspot events showed coordinated patterns of co-occurrence and mutual exclusivity with each other and with tumor suppressor alterations, suggesting genomic context-specific selection. We found localized transcriptional dysregulation at hotspot event loci, and single cells harboring these events converged on a neural crest-like program, linking these structural alterations to a less differentiated cell state. These events were also detectable non-invasively through liquid biopsies and displayed ongoing structural evolution throughout disease progression, a finding with potential clinical utility. Our results provide novel insight into how complex rearrangements shape oncogenesis in osteosarcoma, with broader relevance to other cancers characterized by complex genomes.
- Open Access
- 12 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 8183
Population-based genomic detection of childhood cancer predisposition using newborn dried blood spots
Population-based genomic newborn screening identifying newborns at risk for early-onset cancers has not been evaluated. Here, within a Michigan birth cohort (1987–2020), we identify all children developing a solid or central nervous system malignancy by age 8 years (n = 1948). We perform targeted sequencing of 11 cancer predisposition genes using archived newborn dried blood spot DNA. We find pathogenic or likely-pathogenic germline variants (P/LP) in 6.8% of cases (n = 132): RB1 (n = 69), TP53 (n = 24), SMARCB1 (n = 8), WT1 (n = 7), RET (n = 6), SUFU (n = 6), PTCH1 (n = 4), DICER1 (n = 4), APC (n = 3) and PHOX2B (n = 1). We show approximately 1/27,000 newborns develop an early-onset malignancy with an associated pathogenic or likely-pathogenic variant. Germline variant prevalence is 100% in medullary thyroid carcinoma, 40% in retinoblastoma, and 11–30% across five additional diagnoses, with strong gene–tumor specificity (p < 0.001). P/LP variants are rare in comparison datasets from healthy newborns and gnomAD. Our data support newborn screening for selected cancer-risk genes.
- 12 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 8183
Open AccessPopulation-based genomic detection of childhood cancer predisposition using newborn dried blood spots
Population-based genomic newborn screening identifying newborns at risk for early-onset cancers has not been evaluated. Here, within a Michigan birth cohort (1987–2020), we identify all children developing a solid or central nervous system malignancy by age 8 years (n = 1948). We perform targeted sequencing of 11 cancer predisposition genes using archived newborn dried blood spot DNA. We find pathogenic or likely-pathogenic germline variants (P/LP) in 6.8% of cases (n = 132): RB1 (n = 69), TP53 (n = 24), SMARCB1 (n = 8), WT1 (n = 7), RET (n = 6), SUFU (n = 6), PTCH1 (n = 4), DICER1 (n = 4), APC (n = 3) and PHOX2B (n = 1). We show approximately 1/27,000 newborns develop an early-onset malignancy with an associated pathogenic or likely-pathogenic variant. Germline variant prevalence is 100% in medullary thyroid carcinoma, 40% in retinoblastoma, and 11–30% across five additional diagnoses, with strong gene–tumor specificity (p < 0.001). P/LP variants are rare in comparison datasets from healthy newborns and gnomAD. Our data support newborn screening for selected cancer-risk genes.
- 24 July 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 11 (121)
Genomic correlates of clinical CAR T cell activity
Germline variants influence immune checkpoint inhibitor responses, but their role in engineered immune cell therapies, such as chimeric antigen receptor T cells (CAR T cells), remains unclear. We integrated whole germline sequencing from patients with lymphoma treated with axicabtagene ciloleucel CAR T cell products in the ZUMA-1 and ZUMA-7 clinical trials with detailed biomarker and functional analyses to identify variants influencing clinical toxicity and pharmacokinetics. Putative deleterious variants in STXBP2 ( syntaxin binding protein 2 ) were enriched among patients with toxicity in ZUMA-1, although not confirmed in ZUMA-7. Mechanistically, STXBP2- deficient or variant-expressing T cells triggered increased inflammatory cytokine production and macrophage activation. Conversely, variants in ADAMTSL3 , a TGFβ (transforming growth factor–β) signaling regulator, correlated with protection from toxicity across both trials. Furthermore, variants in PTPN22 , a negative regulator of T cell receptor signaling, strongly associated with enhanced CAR T cell expansion, a key determinant of efficacy. Together, these findings demonstrate that germline genetics shape the safety and activity of engineered immune cell therapies, affecting future design and patient management.
- 24 July 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 11 (121)
Genomic correlates of clinical CAR T cell activity
Germline variants influence immune checkpoint inhibitor responses, but their role in engineered immune cell therapies, such as chimeric antigen receptor T cells (CAR T cells), remains unclear. We integrated whole germline sequencing from patients with lymphoma treated with axicabtagene ciloleucel CAR T cell products in the ZUMA-1 and ZUMA-7 clinical trials with detailed biomarker and functional analyses to identify variants influencing clinical toxicity and pharmacokinetics. Putative deleterious variants in STXBP2 ( syntaxin binding protein 2 ) were enriched among patients with toxicity in ZUMA-1, although not confirmed in ZUMA-7. Mechanistically, STXBP2- deficient or variant-expressing T cells triggered increased inflammatory cytokine production and macrophage activation. Conversely, variants in ADAMTSL3 , a TGFβ (transforming growth factor–β) signaling regulator, correlated with protection from toxicity across both trials. Furthermore, variants in PTPN22 , a negative regulator of T cell receptor signaling, strongly associated with enhanced CAR T cell expansion, a key determinant of efficacy. Together, these findings demonstrate that germline genetics shape the safety and activity of engineered immune cell therapies, affecting future design and patient management.
- Open Access
- 1 June 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (6) , e2600032
Germline Whole-Genome Sequencing in Early-Onset Pediatric Solid Tumors Implicates Novel Risk Factors
PURPOSE: Many children with very early-onset solid tumors remain without an identified germline risk factor after negative panel testing. Whole-genome sequencing (WGS) enables detection of large structural variants (SVs) and rare loss-of-function variants in highly constrained genes that are not routinely captured by standard clinical assays. The additional yield and spectrum of germline findings identified by WGS in this population remain incompletely defined. METHODS: We conducted a retrospective cohort study of children with very early-onset solid or brain tumors evaluated at a tertiary cancer genetic risk clinic with clinically guided germline panel testing. Germline WGS was performed on blood-derived DNA. Analyses focused on pathogenic or likely pathogenic variants in established cancer predisposition genes (CPGs), large SVs (>1,000,000 bp), aneuploidies, and loss-of-function variants in highly constrained genes. RESULTS: One hundred thirty-two patients were included, with median (IQR) age at diagnosis of 1.7 (0.8-3.2) years. Panel testing identified pathogenic CPG variants in 27 of 132 patients (20%). WGS recapitulated panel findings and identified nine additional putative pathogenic variants, increasing yield to 27%. Eight patients (6%) harbored large germline SVs or aneuploidies, including five events not previously recognized. Rare loss-of-function variants in highly constrained genes were identified in 46 patients (35%), many involving pathways relevant to cancer development. Overall, 66 of 132 patients (50%) carried at least one rare germline variant of potential pathogenic relevance. CONCLUSION: In children with very early-onset solid tumors, germline WGS increased detection of potentially pathogenic variants, including novel structural and constrained-gene alterations. These findings support broader consideration of germline WGS in early-onset solid tumors to refine genetic risk assessment and enable discovery of novel susceptibility mechanisms.
- 1 June 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (6) , e2600032
Open AccessGermline Whole-Genome Sequencing in Early-Onset Pediatric Solid Tumors Implicates Novel Risk Factors
PURPOSE: Many children with very early-onset solid tumors remain without an identified germline risk factor after negative panel testing. Whole-genome sequencing (WGS) enables detection of large structural variants (SVs) and rare loss-of-function variants in highly constrained genes that are not routinely captured by standard clinical assays. The additional yield and spectrum of germline findings identified by WGS in this population remain incompletely defined. METHODS: We conducted a retrospective cohort study of children with very early-onset solid or brain tumors evaluated at a tertiary cancer genetic risk clinic with clinically guided germline panel testing. Germline WGS was performed on blood-derived DNA. Analyses focused on pathogenic or likely pathogenic variants in established cancer predisposition genes (CPGs), large SVs (>1,000,000 bp), aneuploidies, and loss-of-function variants in highly constrained genes. RESULTS: One hundred thirty-two patients were included, with median (IQR) age at diagnosis of 1.7 (0.8-3.2) years. Panel testing identified pathogenic CPG variants in 27 of 132 patients (20%). WGS recapitulated panel findings and identified nine additional putative pathogenic variants, increasing yield to 27%. Eight patients (6%) harbored large germline SVs or aneuploidies, including five events not previously recognized. Rare loss-of-function variants in highly constrained genes were identified in 46 patients (35%), many involving pathways relevant to cancer development. Overall, 66 of 132 patients (50%) carried at least one rare germline variant of potential pathogenic relevance. CONCLUSION: In children with very early-onset solid tumors, germline WGS increased detection of potentially pathogenic variants, including novel structural and constrained-gene alterations. These findings support broader consideration of germline WGS in early-onset solid tumors to refine genetic risk assessment and enable discovery of novel susceptibility mechanisms.
- Open Access
Diverse mediators of cancer predisposition uncovered by germline whole genome sequencing of unexplained familial cancers
Cancer frequently clusters in families due to shared environment and genetics. However, many familial cancer cases lack a clinically recognized pathogenic germline variant (PGV). We analyzed germline genomes and family history from 2,726 individuals without a PGV in the All of Us Research Program, including 1,496 cases across 18 cancer types with extensive family history and 1,230 family history-negative, cancer-free controls. We identified allelic series of rare structural variants inactivating MSH2 in individuals with phenotypes consistent with Lynch syndrome and BRCA1 in breast cancer. Cancer polygenic risk scores were enriched in cases and correlated with patterns of cancer diagnoses within families. Exome-wide rare variant analyses nominated six candidate predisposition genes, including TSTD2 and BRAT1 in thyroid and breast cancer, respectively. Overall, polygenic risk and rare variants impacting known genes explained a median of 5% of unexplained familial cancers, increasing to 11% when including newly nominated risk factors.
Open AccessDiverse mediators of cancer predisposition uncovered by germline whole genome sequencing of unexplained familial cancers
Cancer frequently clusters in families due to shared environment and genetics. However, many familial cancer cases lack a clinically recognized pathogenic germline variant (PGV). We analyzed germline genomes and family history from 2,726 individuals without a PGV in the All of Us Research Program, including 1,496 cases across 18 cancer types with extensive family history and 1,230 family history-negative, cancer-free controls. We identified allelic series of rare structural variants inactivating MSH2 in individuals with phenotypes consistent with Lynch syndrome and BRCA1 in breast cancer. Cancer polygenic risk scores were enriched in cases and correlated with patterns of cancer diagnoses within families. Exome-wide rare variant analyses nominated six candidate predisposition genes, including TSTD2 and BRAT1 in thyroid and breast cancer, respectively. Overall, polygenic risk and rare variants impacting known genes explained a median of 5% of unexplained familial cancers, increasing to 11% when including newly nominated risk factors.
- Top Cited Papers
- 10 December 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (35) , 3750-3759
Molecular Characterization Informs Prognosis in Patients With Localized Ewing Sarcoma: A Report From the Children's Oncology Group
PURPOSE: Identifying discrete subgroups associated with treatment response and resistance in localized Ewing sarcoma (EWS) remains a challenge. The primary objective of the Children's Oncology Group (COG) biology study AEWS18B1-Q was to molecularly characterize patients with localized EWS on prospective modern-day trials. PATIENTS AND METHODS: We analyzed clinical and molecular features from patients with localized EWS enrolled on frontline COG trials. All patients had available formalin-fixed paraffin-embedded (FFPE) tissue, frozen tissue, or whole-genome–amplified material. Sequencing was performed for identification of canonical fusions, recurrent copy number alterations (CNAs), and alterations in TP53 and STAG2 . Available tissue was analyzed for loss of STAG2 protein expression. Molecular features were evaluated for their association with cumulative incidence of relapse in univariate and multivariable analyses. RESULTS: Three hundred fifty-one patients had sufficient tissue, which in most cases was extracted from two FFPE slides. EWS canonical fusions were identified in 282 patients (80.3%). Pathogenic mutations in TP53 and STAG2 were identified in 5.1% and 7.6% of patients, respectively. A total of 63.1% of patients were found to have recurrent CNAs. In univariate analysis, there was an increased cumulative incidence of relapse in patients with TP53 mutation (5-year cumulative incidence of relapse 43%, 95% CI [17% to 67%] v 22%, 95% CI [17% to 27%]; Gray's test P = .039), STAG2 mutation (53%, 95% CI [29% to 73%] v 21%, 95% CI [16% to 26%]; P < .001), and recurrent CNAs (30%, 95% CI [22% to 37%] v 16%, 95% CI [9% to 24%]; P = .005). In a multivariable analysis, STAG2 mutation was the only molecular biomarker that remained prognostic. CONCLUSION: This is a prospective validation of the molecular prognostic features of patients with localized EWS receiving standard-of-care therapy on therapeutic clinical trials. Building on previous work, patients with STAG2 mutations were at high risk of relapse.
- 10 December 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (35) , 3750-3759
Top Cited PapersMolecular Characterization Informs Prognosis in Patients With Localized Ewing Sarcoma: A Report From the Children's Oncology Group
PURPOSE: Identifying discrete subgroups associated with treatment response and resistance in localized Ewing sarcoma (EWS) remains a challenge. The primary objective of the Children's Oncology Group (COG) biology study AEWS18B1-Q was to molecularly characterize patients with localized EWS on prospective modern-day trials. PATIENTS AND METHODS: We analyzed clinical and molecular features from patients with localized EWS enrolled on frontline COG trials. All patients had available formalin-fixed paraffin-embedded (FFPE) tissue, frozen tissue, or whole-genome–amplified material. Sequencing was performed for identification of canonical fusions, recurrent copy number alterations (CNAs), and alterations in TP53 and STAG2 . Available tissue was analyzed for loss of STAG2 protein expression. Molecular features were evaluated for their association with cumulative incidence of relapse in univariate and multivariable analyses. RESULTS: Three hundred fifty-one patients had sufficient tissue, which in most cases was extracted from two FFPE slides. EWS canonical fusions were identified in 282 patients (80.3%). Pathogenic mutations in TP53 and STAG2 were identified in 5.1% and 7.6% of patients, respectively. A total of 63.1% of patients were found to have recurrent CNAs. In univariate analysis, there was an increased cumulative incidence of relapse in patients with TP53 mutation (5-year cumulative incidence of relapse 43%, 95% CI [17% to 67%] v 22%, 95% CI [17% to 27%]; Gray's test P = .039), STAG2 mutation (53%, 95% CI [29% to 73%] v 21%, 95% CI [16% to 26%]; P < .001), and recurrent CNAs (30%, 95% CI [22% to 37%] v 16%, 95% CI [9% to 24%]; P = .005). In a multivariable analysis, STAG2 mutation was the only molecular biomarker that remained prognostic. CONCLUSION: This is a prospective validation of the molecular prognostic features of patients with localized EWS receiving standard-of-care therapy on therapeutic clinical trials. Building on previous work, patients with STAG2 mutations were at high risk of relapse.
- Open Access
Genomic correlates of clinical CAR-T cell activity
Chimeric antigen receptor (CAR)-T cell therapies demonstrate potent anti-tumor efficacy in hematologic malignancies, yet clinical outcomes remain unpredictable due to the bespoke nature of the treatment, which is manufactured from each patient’s own T-cells. While germline variants are known to influence response to immune checkpoint inhibitors 1, 2 , their role in CAR-T cell therapy is unknown. Here, we pair whole-genome germline sequencing of lymphoma patients from the ZUMA-1 3 and ZUMA-7 4 clinical trials of axicabtagene ciloleucel, along with correlative biomarkers and functional assays, to ascertain the impact of germline variants on CAR-T cell behavior. Hypothesizing shared mechanisms of the most common toxicities of CAR-T cells, namely cytokine release syndrome (CRS) with hemophagocytic lymphohistiocytosis (HLH)—a hyperinflammatory syndrome driven by T cell overactivation 5 , we first looked within 17 canonical HLH-associated genes 6 , and identified putative deleterious STXBP2 variants in 15% of ZUMA-1 patients with toxicity, which were absent in control subjects who did not experience high grade toxicity. Subjects with these variants had elevated baseline IFN-γ and inflammatory cytokines, findings that were recapitulated in engineered STXBP2 -deficient and STXBP2 -variant-expressing primary CAR-T cells derived from healthy donors. However, STXBP2 variant enrichment was absent in ZUMA-7 for this toxicity phenotype, possibly reflecting differences in underlying disease burden and evolving clinical management between the trials. A more expansive genome-wide analysis revealed ADAMTSL3 (a negative regulator of TGFβ 7 ) as the only gene nominally enriched for putative deleterious variants in both ZUMA-1 and ZUMA-7 among control subjects, suggesting a protective effect. Finally, we focused on associations between germline variants and CAR-T cell expansion after infusion, a more objective and granular continuous variable that is strongly associated with clinical response across most CAR-T products 8 . We found a strong association between PTPN22 , a known negative regulator of T-cell activation 9–12 and an autoimmune risk gene 13, 14 , variant status and CAR-T cell expansion in both ZUMA-1 and ZUMA-7, with the patients having the highest level of CAR-T expansion across clinical trials harboring variants in the gene. Together, these findings demonstrate the first clear association between germline variants and the clinical behavior of engineered immune cell therapies, which has implications for cellular therapy design, monitoring, testing, clinical trial design, and patient care.
Open AccessGenomic correlates of clinical CAR-T cell activity
Chimeric antigen receptor (CAR)-T cell therapies demonstrate potent anti-tumor efficacy in hematologic malignancies, yet clinical outcomes remain unpredictable due to the bespoke nature of the treatment, which is manufactured from each patient’s own T-cells. While germline variants are known to influence response to immune checkpoint inhibitors 1, 2 , their role in CAR-T cell therapy is unknown. Here, we pair whole-genome germline sequencing of lymphoma patients from the ZUMA-1 3 and ZUMA-7 4 clinical trials of axicabtagene ciloleucel, along with correlative biomarkers and functional assays, to ascertain the impact of germline variants on CAR-T cell behavior. Hypothesizing shared mechanisms of the most common toxicities of CAR-T cells, namely cytokine release syndrome (CRS) with hemophagocytic lymphohistiocytosis (HLH)—a hyperinflammatory syndrome driven by T cell overactivation 5 , we first looked within 17 canonical HLH-associated genes 6 , and identified putative deleterious STXBP2 variants in 15% of ZUMA-1 patients with toxicity, which were absent in control subjects who did not experience high grade toxicity. Subjects with these variants had elevated baseline IFN-γ and inflammatory cytokines, findings that were recapitulated in engineered STXBP2 -deficient and STXBP2 -variant-expressing primary CAR-T cells derived from healthy donors. However, STXBP2 variant enrichment was absent in ZUMA-7 for this toxicity phenotype, possibly reflecting differences in underlying disease burden and evolving clinical management between the trials. A more expansive genome-wide analysis revealed ADAMTSL3 (a negative regulator of TGFβ 7 ) as the only gene nominally enriched for putative deleterious variants in both ZUMA-1 and ZUMA-7 among control subjects, suggesting a protective effect. Finally, we focused on associations between germline variants and CAR-T cell expansion after infusion, a more objective and granular continuous variable that is strongly associated with clinical response across most CAR-T products 8 . We found a strong association between PTPN22 , a known negative regulator of T-cell activation 9–12 and an autoimmune risk gene 13, 14 , variant status and CAR-T cell expansion in both ZUMA-1 and ZUMA-7, with the patients having the highest level of CAR-T expansion across clinical trials harboring variants in the gene. Together, these findings demonstrate the first clear association between germline variants and the clinical behavior of engineered immune cell therapies, which has implications for cellular therapy design, monitoring, testing, clinical trial design, and patient care.
- Open Access
Molecular characterization informs prognosis in patients with localized Ewing sarcoma: A report from the Children’s Oncology Group
PURPOSE: Identification of discrete sub-groups associated with treatment response and resistance in localized Ewing sarcoma (EWS) remains a challenge. The primary objective of the Children’s Oncology Group biology study AEWS18B1-Q was to perform molecular characterization of a large cohort of patients with localized Ewing sarcoma treated on prospective trials with modern standard of care therapy. METHODS: We analyzed clinical and molecular features from patients with localized EWS enrolled on AEWS0031, AEWS1031, or INT-0154 frontline trials. All patients had available FFPE tissue, frozen tissue, or whole-genome amplified material. Sequencing was performed for identification of canonical fusions, recurrent copy number alterations (CNAs), and alterations in TP53 and STAG2 . Where available, tissue was analyzed for loss of STAG2 protein expression. Molecular features were evaluated for their association with cumulative incidence of relapse in univariate and multivariable analyses. RESULTS: Three hundred and fifty-one cases had sufficient tissue, which in most cases was extracted from two FFPE slides. EWS canonical fusions were identified in 282 cases (80.3%). Pathogenic mutations in TP53 and STAG2 were identified in 5.1% and 7.6% of cases, respectively and 63.1% of cases were found to have recurrent CNAs. In univariate analysis, there was an increased cumulative incidence of relapse in patients with TP53 mutation (5-year cumulative incidence of relapse 43%, CI [17%, 67%] vs. 22%, CI [17%, 27%]; Gray’s test P = 0.039), STAG2 mutation (53%, CI [29%, 73%] vs. 21%, CI [16%, 26%]; P < 0.001), and recurrent CNAs (30%, CI [22%, 37%] vs. 16%, CI [9%, 24%]; P = 0.005). In a multivariable analysis, STAG2 mutation was the only molecular biomarker that remained prognostic. CONCLUSION: This is a prospective validation of the molecular prognostic features of localized EWS receiving standard of care therapy on therapeutic clinical trials. Building on prior work, patients with STAG2 mutations were at high risk of relapse. CONTEXT: Key Objective: To determine if molecular features can identify clinically relevant disease sub-groups applicable to frontline clinical trial design among patients with localized Ewing sarcoma. Knowledge Generated: Among 351 patients with localized Ewing sarcoma treated on prospective trials, canonical fusions were identified in 80% of cases. In a multivariable analysis of patients with genomically defined Ewing sarcoma, the presence of STAG2 mutations identified a high-risk population. Relevance (added by Associate Editor)
Open AccessMolecular characterization informs prognosis in patients with localized Ewing sarcoma: A report from the Children’s Oncology Group
PURPOSE: Identification of discrete sub-groups associated with treatment response and resistance in localized Ewing sarcoma (EWS) remains a challenge. The primary objective of the Children’s Oncology Group biology study AEWS18B1-Q was to perform molecular characterization of a large cohort of patients with localized Ewing sarcoma treated on prospective trials with modern standard of care therapy. METHODS: We analyzed clinical and molecular features from patients with localized EWS enrolled on AEWS0031, AEWS1031, or INT-0154 frontline trials. All patients had available FFPE tissue, frozen tissue, or whole-genome amplified material. Sequencing was performed for identification of canonical fusions, recurrent copy number alterations (CNAs), and alterations in TP53 and STAG2 . Where available, tissue was analyzed for loss of STAG2 protein expression. Molecular features were evaluated for their association with cumulative incidence of relapse in univariate and multivariable analyses. RESULTS: Three hundred and fifty-one cases had sufficient tissue, which in most cases was extracted from two FFPE slides. EWS canonical fusions were identified in 282 cases (80.3%). Pathogenic mutations in TP53 and STAG2 were identified in 5.1% and 7.6% of cases, respectively and 63.1% of cases were found to have recurrent CNAs. In univariate analysis, there was an increased cumulative incidence of relapse in patients with TP53 mutation (5-year cumulative incidence of relapse 43%, CI [17%, 67%] vs. 22%, CI [17%, 27%]; Gray’s test P = 0.039), STAG2 mutation (53%, CI [29%, 73%] vs. 21%, CI [16%, 26%]; P < 0.001), and recurrent CNAs (30%, CI [22%, 37%] vs. 16%, CI [9%, 24%]; P = 0.005). In a multivariable analysis, STAG2 mutation was the only molecular biomarker that remained prognostic. CONCLUSION: This is a prospective validation of the molecular prognostic features of localized EWS receiving standard of care therapy on therapeutic clinical trials. Building on prior work, patients with STAG2 mutations were at high risk of relapse. CONTEXT: Key Objective: To determine if molecular features can identify clinically relevant disease sub-groups applicable to frontline clinical trial design among patients with localized Ewing sarcoma. Knowledge Generated: Among 351 patients with localized Ewing sarcoma treated on prospective trials, canonical fusions were identified in 80% of cases. In a multivariable analysis of patients with genomically defined Ewing sarcoma, the presence of STAG2 mutations identified a high-risk population. Relevance (added by Associate Editor)
- Top Cited Papers
- 3 January 2025
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 387 (6729) , eadq0071
Rare germline structural variants increase risk for pediatric solid tumors
Pediatric solid tumors are a leading cause of childhood disease mortality. In this work, we examined germline structural variants (SVs) as risk factors for pediatric extracranial solid tumors using germline genome sequencing of 1765 affected children, their 943 unaffected parents, and 6665 adult controls. We discovered a sex-biased association between very large (>1 megabase) germline chromosomal abnormalities and increased risk of solid tumors in male children. The overall impact of germline SVs was greatest in neuroblastoma, where we uncovered burdens of ultrarare SVs that cause loss of function of highly expressed, mutationally constrained genes, as well as noncoding SVs predicted to disrupt chromatin domain boundaries. Collectively, we estimate that rare germline SVs explain 1.1 to 5.6% of pediatric cancer liability, establishing them as an important component of disease predisposition.
- 3 January 2025
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 387 (6729) , eadq0071
Top Cited PapersRare germline structural variants increase risk for pediatric solid tumors
Pediatric solid tumors are a leading cause of childhood disease mortality. In this work, we examined germline structural variants (SVs) as risk factors for pediatric extracranial solid tumors using germline genome sequencing of 1765 affected children, their 943 unaffected parents, and 6665 adult controls. We discovered a sex-biased association between very large (>1 megabase) germline chromosomal abnormalities and increased risk of solid tumors in male children. The overall impact of germline SVs was greatest in neuroblastoma, where we uncovered burdens of ultrarare SVs that cause loss of function of highly expressed, mutationally constrained genes, as well as noncoding SVs predicted to disrupt chromatin domain boundaries. Collectively, we estimate that rare germline SVs explain 1.1 to 5.6% of pediatric cancer liability, establishing them as an important component of disease predisposition.
- Open Access
Rare germline structural variants increase risk for pediatric solid tumors
A bstract: Pediatric solid tumors are rare malignancies that represent a leading cause of death by disease among children in developed countries. The early age-of-onset of these tumors suggests that germline genetic factors are involved, yet conventional germline testing for short coding variants in established predisposition genes only identifies pathogenic events in 10-15% of patients. Here, we examined the role of germline structural variants (SVs)—an underexplored form of germline variation—in pediatric extracranial solid tumors using germline genome sequencing of 1,766 affected children, their 943 unaffected relatives, and 6,665 adult controls. We discovered a sex-biased association between very large (>1 megabase) germline chromosomal abnormalities and a four-fold increased risk of solid tumors in male children. The overall impact of germline SVs was greatest in neuroblastoma, where we revealed burdens of ultra-rare SVs that cause loss-of-function of highly expressed, mutationally intolerant, neurodevelopmental genes, as well as noncoding SVs predicted to disrupt three-dimensional chromatin domains in neural crest-derived tissues. Collectively, our results implicate rare germline SVs as a predisposing factor to pediatric solid tumors that may guide future studies and clinical practice.
Open AccessRare germline structural variants increase risk for pediatric solid tumors
A bstract: Pediatric solid tumors are rare malignancies that represent a leading cause of death by disease among children in developed countries. The early age-of-onset of these tumors suggests that germline genetic factors are involved, yet conventional germline testing for short coding variants in established predisposition genes only identifies pathogenic events in 10-15% of patients. Here, we examined the role of germline structural variants (SVs)—an underexplored form of germline variation—in pediatric extracranial solid tumors using germline genome sequencing of 1,766 affected children, their 943 unaffected relatives, and 6,665 adult controls. We discovered a sex-biased association between very large (>1 megabase) germline chromosomal abnormalities and a four-fold increased risk of solid tumors in male children. The overall impact of germline SVs was greatest in neuroblastoma, where we revealed burdens of ultra-rare SVs that cause loss-of-function of highly expressed, mutationally intolerant, neurodevelopmental genes, as well as noncoding SVs predicted to disrupt three-dimensional chromatin domains in neural crest-derived tissues. Collectively, our results implicate rare germline SVs as a predisposing factor to pediatric solid tumors that may guide future studies and clinical practice.